Skip to main content
ASTAL LABORATORIES LIMITED logo

ASTAL LABORATORIES LIMITED — Investor Relations & Filings

Ticker · 512600 ISIN · INE307N01014 LEI · 8945004HO2WCBQ0CJ976 BSE.NS Manufacturing
Filings indexed 443 across all filing types
Latest filing 2025-08-12 Regulatory Filings
Country IN India
Listing BSE.NS 512600

About ASTAL LABORATORIES LIMITED

https://miel.co.in/

Astal Laboratories Limited is a pharmaceutical organization engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company's product portfolio encompasses various dosage forms, including tablets, capsules, liquid orals, and topical preparations. It operates across several therapeutic categories, such as anti-infectives, analgesics, and gastrointestinal treatments. Astal Laboratories prioritizes quality control and adheres to established manufacturing standards to ensure the safety and efficacy of its products. The company focuses on providing accessible healthcare solutions through a robust distribution network and a commitment to research-driven formulation development.

Recent filings

Filing Released Lang Actions
Submission of quarterly results for the quarter ended 30th June, 2025 pursuant to the Regulation 33 of SEBI (LODR) Regulations, 2025.
Regulatory Filings
2025-08-12 English
Submission of Outcome of board meeting held on 12th August, 2025.
Regulatory Filings
2025-08-12 English
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve Submission of prior intimation ....
Regulatory Filings
2025-08-06 English
Submission on certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter June 2025.
Regulatory Filings
2025-07-15 English
Submission of intimation of trading window closure.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) informing about the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It mentions the period of closure related to the upcoming unaudited financial results for the quarter ended June 30, 2025, but does not contain any financial data or results itself. The document is short (1984 characters) and serves as an announcement or intimation rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2025-06-26 English
Submission of newspaper publication of audited financial results for the quarter and year ended 31st March, 2025.
Regulatory Filings
2025-05-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.